Institute of Sports Medicine, Beijing Key Laboratory of Sports Injuries, Peking University Third Hospital, Beijing, China.
Medical Imaging Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Phytother Res. 2021 Nov;35(11):5921-5935. doi: 10.1002/ptr.7204. Epub 2021 Jul 2.
The aim of this systematic review was to evaluate the efficacy and safety of all types of Curcuma longa extract versus placebo for knee osteoarthritis (OA) treatment. The research was conducted by using the databases of PubMed, Embase, Scopus, and Cochrane Library through April 2021. Randomized controlled trials (RCTs) that compared the effect of Curcuma longa extract with placebo for patients with knee OA were considered eligible. The pooled results were expressed as mean differences or relative risks with 95% confidence intervals. A total of 10 RCTs with 783 patients were eligible for this meta-analysis. The pooled analysis showed that Curcuma longa extract was associated with significantly better pain relief and functional improvement compared with placebo for knee OA. Moreover, the smallest effect sizes of VAS for pain and WOMAC total score exceeded the minimum clinically important differences (MCIDs). Current evidence indicates that, compared with placebo, Curcuma longa extract has more benefit in pain relief and functional improvement for symptomatic knee OA. However, considering the potential heterogeneity in the included studies, more future high-quality RCTs with large sample sizes are necessary to confirm the benefits of Curcuma longa extract on knee OA.
本系统评价的目的是评估各种姜黄提取物与安慰剂治疗膝骨关节炎 (OA) 的疗效和安全性。研究通过使用 PubMed、Embase、Scopus 和 Cochrane Library 数据库进行，检索时间截至 2021 年 4 月。纳入比较姜黄提取物与安慰剂治疗膝骨关节炎患者效果的随机对照试验 (RCT)。汇总结果表示为均数差或 95%置信区间的相对风险。共有 10 项 RCT 纳入 783 名患者符合本 meta 分析的纳入标准。汇总分析表明，与安慰剂相比，姜黄提取物治疗膝骨关节炎的疼痛缓解和功能改善更显著。此外，疼痛视觉模拟量表 (VAS)和 WOMAC 总评分的最小效应量超过了最小临床重要差异 (MCID)。目前的证据表明，与安慰剂相比，姜黄提取物在缓解疼痛和改善膝骨关节炎症状的功能方面有更多益处。然而，考虑到纳入研究的潜在异质性，需要更多未来高质量、大样本量的 RCT 来证实姜黄提取物对膝骨关节炎的益处。
